<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046522</url>
  </required_header>
  <id_info>
    <org_study_id>MIGLEV-21</org_study_id>
    <nct_id>NCT05046522</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.</brief_title>
  <official_title>A Double-blind Randomised Controlled Study to Evaluate the Effectiveness of Orally-dosed Palmitoylethanolamide (PEA) Compared to Placebo for Reducing Pain Severity and Duration of Migraines in Otherwise Healthy Participants Aged 18 Years and Older.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDC Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDC Clinical Pty Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind randomised controlled study to evaluate the effectiveness of&#xD;
      orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and&#xD;
      duration of migraines in otherwise healthy participants aged 18 years and older.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in migraine pain/severity as assessed by VAS for pain Migraine Pain/Severity</measure>
    <time_frame>Baseline (onset of migraine), 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 2 hours 30 minutes, 3 hours, 3 hour 30 minutes, 4 hours, 5 hours, 6 hours, 7 hours and 8 hours (primary endpoint).</time_frame>
    <description>Change in migraine pain/severity as assessed by Visual Analog Scale for pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Migraine Duration</measure>
    <time_frame>Baseline (onset of migraine), 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 2 hours 30 minutes, 3 hours, 3 hour 30 minutes, 4 hours, 5 hours, 6 hours, 7 hours and 8 hours (primary endpoint).</time_frame>
    <description>Change in migraine duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief medication use</measure>
    <time_frame>Baseline (onset of migraine), 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 2 hours 30 minutes, 3 hours, 3 hour 30 minutes, 4 hours, 5 hours, 6 hours, 7 hours and 8 hours (primary endpoint).</time_frame>
    <description>Change in pain relief medication use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Palmitoylethanolamide sold as Levagen +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palmitoylethanolamide in capsule form - taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A comparator placebo capsule - Maltodextrin and microcrystalline cellulose mix</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A comparator capsule taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palmitoylethanolamide sold as Levagen +</intervention_name>
    <description>Investigational product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.</description>
    <arm_group_label>Palmitoylethanolamide sold as Levagen +</arm_group_label>
    <other_name>Levagen+</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator - maltodextrin and microcrystalline cellulose mix</intervention_name>
    <description>Placebo product to be taken as a 700mg (2 x 350mg) dosage at onset of migraine. If unresolved at 2 hours post onset of migraine, a second dose of 700mg (2 x 350mg) is to be taken.</description>
    <arm_group_label>A comparator placebo capsule - Maltodextrin and microcrystalline cellulose mix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged over 18&#xD;
&#xD;
          -  No recent history (within 2 years) of clinically significant medical conditions&#xD;
             including, but not limited to, malignancy (and treatment for malignancy),&#xD;
             cardiovascular, neurological, psychiatric, renal, immunological, endocrine (including&#xD;
             uncontrolled diabetes or thyroid disease) or haematological abnormalities that are&#xD;
             uncontrolled*.&#xD;
&#xD;
          -  Participant's full agreement and ability to consent to participation in the study&#xD;
&#xD;
          -  At least 1 migraine (not headache) episode every 2 months as classified according to&#xD;
             the International Classification of Headache Disorders, 3rd edition (ICHD3) for&#xD;
             migraines published by the International Headache Society as detailed in section&#xD;
             &quot;Classification&quot;&#xD;
&#xD;
          -  Access to a computer or smartphone for completing online questionnaires and events.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of long-term medication (unless for controlled medical condition as above)&#xD;
&#xD;
          -  Pregnant, trying to get pregnant or lactating women^&#xD;
&#xD;
          -  Chronic past and/or current alcohol use (greater than 14 alcoholic drinks week)&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Allergic or hypersensitive to any of the ingredients in the active or placebo formula&#xD;
&#xD;
          -  Use of preventative migraine medication&#xD;
&#xD;
          -  Migraines that have reported:&#xD;
&#xD;
               -  To occur on 15 or more days/month for more than 3 months, which, on at least 8&#xD;
                  days/month, has the features of migraine headache.&#xD;
&#xD;
               -  A debilitating attack lasting for more than 72 hours.&#xD;
&#xD;
               -  A seizure&#xD;
&#xD;
                    -  A medical condition will be considered uncontrolled if the participant&#xD;
                       reports ongoing treatment, a change of either medication type or dose in the&#xD;
                       past 3 months or any change in symptoms within the past 3 months.&#xD;
&#xD;
                         -  Any person suspecting they may be pregnant (e.g. missed period, nausea,&#xD;
                            fatigue) will be directed to attend their GP for a pregnancy test prior&#xD;
                            to enrolment in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Briskey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RDC Global Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Rao, PhD</last_name>
    <phone>+61 414 488 559</phone>
    <email>amanda@rdcglobal.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Briskey, PhD</last_name>
    <phone>+61 421 784 077</phone>
    <email>d.briskey@uq.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RDC Global Pty Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Rao, PhD</last_name>
      <phone>+61 414 488 559</phone>
      <email>amanda@rdcglobal.com.au</email>
    </contact>
    <contact_backup>
      <last_name>David Briskey, PhD</last_name>
      <phone>+61 421 784 077</phone>
      <email>d.briskey@uq.edu.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palmidrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

